Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Effectivity of Erythropoietin-Alpha between Fixed- and Adjusted-Dose in Chronic Kidney Disease Patients With Anemia on Hemodialysis

Folia Medica Indonesiana · Vol. 55 No. 4 (2020) · hlm. 306–306

DOI
10.20473/fmi.v55i4.24494
ISSN
2355-8393, 2599-056X
Terbit
2020-01-13
Penerbit
Airlangga University
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0/

Abstrak

Anemia is a common complication in chronic kidney disease (CKD) patient with hemodialysis. The cause of anemia is mainly due to erythropoetin deficiency because the kidneys as a erythropoetin producer are damaged. The most appropriate management of anemia in CKD with hemodialysis is the administration of Erythropoietin Stimulating Agent (ESA) or erythropoetin (Epo). The effectiveness of Epo therapy is influenced by the type of Epo used, the dose of Epo given, the route and frequency of Epo administration, as well as several conditions that affect it such as infection or inflammation, absolute and functional iron deficiency, and malnutrition. Therapeutic targets can be achieved if the dose given is in accordance with the needs of the patient, based on the patient's weight The purpose of this study was to determine the differences in the achievement of Epo-alpha fixed-dose administration compared with adjustment-dose in patients with CKD anemia with hemodialysis after administration of Epo-alpha for 4 weeks in outpatient poly hemodialysis units at Bhayangkara H.S Hospital. Samsoeri Mertojoso Surabaya. In this study, there were 20 patients who met the inclusion criteria (15 male and 5 female) divided into 2 groups, 10 patients in the fixed-dose group and 10 patients in the adjustment-dose group. In the fixed-dose group with a adequacy level of 132.25 ± 29.17, the average Hb change achievement was 0.68 ± 0.63 g / dL (p=0.008), whereas in the adjustment-dose group the achievement of the average Hb change the mean was 1.09 ± 0.82 g / dL (p=0.002). For the Hct parameter, the average Hct change in the fixed-dose group was 2.77 ± 2.23% (p=0.004), while in the adjustment-dose group the average Hct change achievement was 4.02 ± 2.63 g / dL (p=0.001). There was no difference in the achievement of the effectiveness of Epo on the two parameters Hb (p=0.224) and Hct (p=0.256) in the fixed-dose group compared with adjustment-dose.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 86 tautan kepenulisan bersama · 25 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • Rumah Sakit Dokter Soetomo
  • State University of Makassar
  • RSUD Prof. Dr. Saiful Anwar Malang
  • Rumah Sakit Umum Haji Surabaya
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Mariyatul QibtiyahRumah Sakit Dokter Soetomo3
Didik HasmonoUniversitas Airlangga2
Nun ZairinaRumah Sakit Dokter Soetomo2
Mahardian RahmadiUniversitas Airlangga2
Junaidi KhotibUniversitas Airlangga2
Eddy RahardjoUniversitas Airlangga2
Dewi Wara ShintaUniversitas Airlangga2
Dwi Hari SusiloUniversitas Airlangga2
Andi Bulqiah NurState University of Makassar1
Moch YusufUniversitas Airlangga1
YulistianiUniversitas Airlangga1
Wulida Nuril FajriyahState University of Makassar1
Zam Zami JauhariUniversitas Airlangga1
Diyah WahyuniUniversitas Airlangga1
Ramadi Satryo WicaksonoAfiliasi tidak diketahui1
Abdul Kadir JaelaniAfiliasi tidak diketahui1
Vini Siane TanaemUniversitas Airlangga1
Binti MuzayyanahUniversitas Airlangga1
Nuraida WisudaniAfiliasi tidak diketahui1
Anak Agung Ngurah Putra Riana PrasetyaUniversitas Airlangga1
Bayu Dharma ShantiAfiliasi tidak diketahui1
Eddy Zarkaty MRumah Sakit Umum Haji Surabaya1
Teri Wina HerwatiUniversitas Airlangga1
Desantika WuryanaRSUD Prof. Dr. Saiful Anwar Malang1
Bagus Putu Putra SuryanaRSUD Prof. Dr. Saiful Anwar Malang1
Octaviana Maria SimbolonUniversitas Airlangga1
I Dg UgrasenaUniversitas Airlangga1
Soedarsono SoedarsonoRumah Sakit Dokter Soetomo1
Herni SetyawatiUniversitas Airlangga1
Umi FatmawatiRumah Sakit Dokter Soetomo1
Febriansyah Nur UtomoRumah Sakit Dokter Soetomo1
Bambang PermonoRumah Sakit Dokter Soetomo1
Mia Ratwita AndarsiniUniversitas Airlangga1
Levana RismayantiUniversitas Airlangga1
Nur OktaviaUniversitas Airlangga1
Unedo Hence Markus SihombingAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Effectivity of Erythropoietin-Alpha between Fixed- and Adjusted-Dose in Chronic Kidney Disease Patients With Anemia on Hemodialysis</dc:title><dc:creator>Mida Purwiningtyas</dc:creator><dc:creator>Yulistiani Yulistiani</dc:creator><dc:creator>Budi Suprapti</dc:creator><dc:creator>Bayu Dharma Santi</dc:creator><dc:subject>chronic kidney disease</dc:subject><dc:subject>hemodialysis</dc:subject><dc:subject>anemia of chronic kidney disease</dc:subject><dc:subject>hemoglobin response</dc:subject><dc:subject>hematocrit</dc:subject><dc:subject>erythropoiesis-stimulating agents</dc:subject><dc:subject>dose-response relationship</dc:subject><dc:subject>iron deficiency</dc:subject><dc:subject>malnutrition</dc:subject><dc:subject>inflammation</dc:subject><dc:subject>infection</dc:subject><dc:description xml:lang="en">Anemia is a common complication in chronic kidney disease (CKD) patient with hemodialysis. The cause of anemia is mainly due to erythropoetin deficiency because the kidneys as a erythropoetin producer are damaged. The most appropriate management of anemia in CKD with hemodialysis is the administration of Erythropoietin Stimulating Agent (ESA) or erythropoetin (Epo). The effectiveness of Epo therapy is influenced by the type of Epo used, the dose of Epo given, the route and frequency of Epo administration, as well as several conditions that affect it such as infection or inflammation, absolute and functional iron deficiency, and malnutrition. Therapeutic targets can be achieved if the dose given is in accordance with the needs of the patient, based on the patient's weight The purpose of this study was to determine the differences in the achievement of Epo-alpha fixed-dose administration compared with adjustment-dose in patients with CKD anemia with hemodialysis after administration of Epo-alpha for 4 weeks in outpatient poly hemodialysis units at Bhayangkara H.S Hospital. Samsoeri Mertojoso Surabaya. In this study, there were 20 patients who met the inclusion criteria (15 male and 5 female) divided into 2 groups, 10 patients in the fixed-dose group and 10 patients in the adjustment-dose group. In the fixed-dose group with a adequacy level of 132.25 ± 29.17, the average Hb change achievement was 0.68 ± 0.63 g / dL (p=0.008), whereas in the adjustment-dose group the achievement of the average Hb change the mean was 1.09 ± 0.82 g / dL (p=0.002). For the Hct parameter, the average Hct change in the fixed-dose group was 2.77 ± 2.23% (p=0.004), while in the adjustment-dose group the average Hct change achievement was 4.02 ± 2.63 g / dL (p=0.001). There was no difference in the achievement of the effectiveness of Epo on the two parameters Hb (p=0.224) and Hct (p=0.256) in the fixed-dose group compared with adjustment-dose.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2020-01-13</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v55i4.24494</dc:identifier><dc:identifier>10.20473/fmi.v55i4.24494</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 55 No 4 (2020); 306-306</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/24494/13272</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>